Figure 3

Melanoma patients with enhanced ATF6 and PERK branch activity show decreased survival. High ATF6 and PERK branch activity shows negative impact on the survival of melanoma patients. Kaplan-Meier analyses were performed on the activity of ATF6 (a–b), PERK (d–e) and IRE1 pathways (g–h) using mRNA microarray datasets previously published16. Expression of mRNA levels of the ATF6 (c), the PERK (f) and the IRE1 pathway (i) was determined in nevi and melanoma samples from datasets previously published17.